tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Dermatomycoses D003881 17 associated lipids
Dermatomyositis D003882 2 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diarrhea D003967 32 associated lipids
Digestive System Diseases D004066 3 associated lipids
Down Syndrome D004314 18 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Dyspnea D004417 10 associated lipids
Earache D004433 2 associated lipids
Echinostomiasis D004451 1 associated lipids
Ecthyma, Contagious D004474 1 associated lipids
Eczema D004485 4 associated lipids
Edema D004487 152 associated lipids
Encephalitis D004660 15 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Epididymitis D004823 1 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Erythema D004890 22 associated lipids
Erythema Nodosum D004893 5 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Erythroplasia D004919 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Exanthema D005076 11 associated lipids
Eye Diseases D005128 12 associated lipids
Facial Dermatoses D005148 7 associated lipids
Facial Neoplasms D005153 3 associated lipids
Fatigue D005221 10 associated lipids
Fatty Liver D005234 48 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Fever D005334 35 associated lipids
Fibrosis D005355 23 associated lipids
Fistula D005402 8 associated lipids
Folliculitis D005499 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Foot Dermatoses D005533 3 associated lipids
Fox-Fordyce Disease D005588 2 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Candinas D et al. Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. 1994 Transplant. Proc. pmid:7527959
Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. 1994 Transplant. Proc. pmid:7527960
Neuhaus PJ Optimised first-line FK506-based protocols in liver transplantation: experience from the University Hospital Rudolf Virchow, Berlin. 1994 Transplant. Proc. pmid:7527961
Sewing KF Pharmacokinetics, dosing principles, and blood level monitoring of FK506. 1994 Transplant. Proc. pmid:7527962
Nishikawa K et al. Experimental studies of vascularized joint allografts in rats. 1994 Transplant. Proc. pmid:7513482
Fukuzawa M and Okada A Analysis of mouse xenogeneic T-cell responses and the effect of FK 506 on these responses and on xeno-skin graft rejection. 1994 Transplant. Proc. pmid:7513483
Petuch BR et al. Microbial transformation of immunosuppressive compounds. III. Glucosylation of immunomycin (FR 900520) and FK 506 by Bacillus subtilis ATCC 55060. 1994 J. Ind. Microbiol. pmid:7513528
Shaeffer MS et al. Interaction between FK506 and erythromycin. 1994 Ann Pharmacother pmid:7513563
Cardenas ME et al. Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. 1994 EMBO J. pmid:7529175
Burkhalter EL et al. Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone. 1994 J. Hepatol. pmid:7529272
Kawano K et al. Evidence that FK506 alleviates ischemia/reperfusion injury to the rat liver: in vivo demonstration for suppression of TNF-a production in response to endotoxemia. 1994 Eur Surg Res pmid:7516291
Morozumi K and Takeda A [Kidney disorders induced by immunosuppressive agents]. 1994 Nippon Naika Gakkai Zasshi pmid:7529294
Hashimoto T et al. Treatment with FK506 prevents rejection of rat colon allografts. 1994 Transplantation pmid:7516586
Alamartine E et al. In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells. 1994 Nephrol. Dial. Transplant. pmid:7529381
Konishi M et al. Effects of FK506 on surface antigen expression by regenerating thymocytes after sublethal irradiation in the rat. 1994 Thymus pmid:7532330
Krentz AJ et al. Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506. 1994 Transplantation pmid:7516590
Shapiro R et al. A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. 1994 Clin Transplant pmid:7532475
Ludwig B et al. Characterization of Mip proteins of Legionella pneumophila. 1994 FEMS Microbiol. Lett. pmid:7516906
Murthy JN et al. Identification of a 14 kDa FK-506/rapamycin binding immunophilin from calf thymus. 1994 Clin. Biochem. pmid:7532556
Donnelly JG and Soldin SJ Partial characterization of a 52 kDa CsA/FK506/rapamycin binding protein. 1994 Clin. Biochem. pmid:7532557
Murase N et al. Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts. 1994 Transplant. Proc. pmid:7518139
Fujisaki S et al. Effects of preformed antibodies induced by whole blood transfusion on small bowel transplantation. 1994 Transplant. Proc. pmid:7518140
Spada M et al. Monitoring of intestinal myoelectrical activity after isolated small bowel transplantation in FK 506 immunosuppressed pigs. 1994 Transplant. Proc. pmid:7518141
Spada M et al. Morphology of acute rejection and observation of lymphoproliferative hyperplastic reaction in FK 506 treated pigs after small bowel transplantation. 1994 Transplant. Proc. pmid:7518142
Cakaloglu Y et al. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. 1994 Hepatology pmid:7519161
Luan S et al. Light-regulated, tissue-specific immunophilins in a higher plant. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7508125
Blazar BR et al. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. 1994 J. Immunol. pmid:7519216
Laifer SA et al. Pregnancy after cardiac transplantation. 1994 Am J Perinatol pmid:7519426
Yoshikawa N et al. Effect of FK-506 on xenografted human Graves' thyroid tissue is severe combined immunodeficient mice. 1994 Clin. Endocrinol. (Oxf) pmid:7519528
Kao PN et al. Cloning and expression of cyclosporin A- and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90. 1994 J. Biol. Chem. pmid:7519613
Masaoka T Problems of bone marrow transplantation in Japan. 1994 Transplant. Proc. pmid:7520634
Okano K et al. Ameliorative effect of FK 506 on cold ischemia reperfusion injury of the rat liver. 1994 Transplant. Proc. pmid:7520635
Surdacka E et al. [New immunosuppressive drugs in transplantation]. 1994 Prz. Lek. pmid:7532870
Kim YI et al. FK 506 prevents critical warm ischemia damage to the pig liver and improves hepatic microcirculation. 1994 Transplant. Proc. pmid:7520636
Hirai T et al. A short course of FK506 can induce limited donor-specific graft acceptance. 1994 Ann. Thorac. Surg. pmid:7520685
Kuwano K and Arai S The inhibitory effect of FK506 on cytotoxic T-lymphocyte killing. 1994 Immunol. Lett. pmid:7536706
Metcalfe S et al. FK506 and cyclosporin A each inhibit antigen-specific signaling in the T cell line 171 in the absence of a calcium signal. 1994 Cell. Immunol. pmid:7522130
Nichols RA et al. Calcineurin-mediated protein dephosphorylation in brain nerve terminals regulates the release of glutamate. 1994 J. Biol. Chem. pmid:7522234
Nakagawa H et al. Tacrolimus ointment for atopic dermatitis. 1994 Lancet pmid:7522297
Sharkey J and Butcher SP Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. 1994 Nature pmid:7522303
Schleuning M et al. Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives. 1994 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7523957
Perotti BY et al. HPLC assay for FK 506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. 1994 Pharm. Res. pmid:7524055
FDA approved new drug bulletin: aprotinin injection (trasylol), tacrolimus (prograf). 1994 RN pmid:7524131
Apanay DC et al. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. 1994 Transplantation pmid:7524202
Steinmüller TM et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. 1994 Transplantation pmid:7524203
Ko S et al. The pharmacokinetic benefits of newly developed liposome-incorporated FK506. 1994 Transplantation pmid:7526494
Shapiro R et al. Renal transplantation at the University of Pittsburgh: the impact of FK506. 1994 Clin Transpl pmid:7547544
Undre N and Möller A Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. 1994 Transpl. Int. pmid:11271189
Holländer GA et al. Disruption of T cell development and repertoire selection by calcineurin inhibition in vivo. 1994 Transplantation pmid:7526495
Yano K et al. Effects of intrahepatic arterial and intraportal administration of FK 506 on liver allograft survival in rats. 1994 Transpl. Int. pmid:11271200
Ishioka M et al. FK506 treatment of noninfectious uveitis. 1994 Am. J. Ophthalmol. pmid:7526689
Devlin J et al. Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients. 1994 Transpl. Int. pmid:11271207
Carroll PB et al. Effect of tacrolimus (FK506) in dystrophic epidermolysis bullosa: rationale and preliminary results. 1994 Arch Dermatol pmid:7526802
Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. 1994 Transpl. Int. pmid:11271216
Iwata H et al. Suppression of allograft responses by combining alloantigen-specific i.v. pre-sensitization with suboptimal doses of rapamycin. 1994 Int. Immunol. pmid:7511931
Mayrleitner M et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506 binding protein: effect of FKBP-12 on single channel activity of the skeletal muscle ryanodine receptor. 1994 Cell Calcium pmid:7511990
Hamajima E et al. Effects of FK506, an immunosuppressive agent, on genesis of water-immersion stress-induced gastric lesions in rats. 1994 Dig. Dis. Sci. pmid:7512015
Matsumoto T et al. Preventive effect of immunosuppressive agents against indomethacin-induced small intestinal ulcers in rats. 1994 Dig. Dis. Sci. pmid:7512017
Lhoëst G et al. Isolation and identification of a novel isomerized epoxide metabolite of FK-506 from erythromycin-induced rabbit liver microsomes. 1993 Sep-Oct Drug Metab. Dispos. pmid:7694828
Iwasaki K et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. 1993 Nov-Dec Drug Metab. Dispos. pmid:7507815
Fukuse T et al. Combined therapy with FK-506 and cyclosporine for canine lung allotransplantation: immunosuppressive effects and blood trough levels. 1993 Nov-Dec J. Heart Lung Transplant. pmid:7508750
Morris RE New small molecule immunosuppressants for transplantation: review of essential concepts. 1993 Nov-Dec J. Heart Lung Transplant. pmid:7508752
Schreier MH Immunophilins and immunosuppression. 1993 Mar-Apr Clin. Exp. Rheumatol. pmid:7686830
Piekoszewski W et al. Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. 1993 Jul-Aug Drug Metab. Dispos. pmid:7690698
Kobayashi J et al. A new rat infection-heart transplant model: effect of infection on graft survival studies. 1993 Jul-Aug J. Heart Lung Transplant. pmid:7690253
Lane BC et al. Evaluation of calcineurin's role in the immunosuppressive activity of FK 506, related macrolactams, and cyclosporine. 1993 Transplant. Proc. pmid:7679829
Celli S et al. Long-term survival of heart and liver xenografts with splenectomy and FK 506. 1993 Transplant. Proc. pmid:7679830
Japanese study of FK 506 on kidney transplantation: results of late phase II study. 1993 Transplant. Proc. pmid:7679831
Kobayashi M et al. Production of monoclonal antibody against recombinant human FKBP-12 and subcellular localization of FKBP-12 in human mononuclear and polymorphonuclear cells. 1993 Transplant. Proc. pmid:7679832
Randhawa PS et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. 1993 Am. J. Surg. Pathol. pmid:7680544
Xu RX et al. Heteronuclear 3D NMR studies of water bound to an FK506 binding protein/immunosuppressant complex. 1993 Biochemistry pmid:7680570
Egan DA et al. Equilibrium denaturation of recombinant human FK binding protein in urea. 1993 Biochemistry pmid:7680574
Lionetti P et al. Activation of mucosal V beta 3+ T cells and tissue damage in human small intestine by the bacterial superantigen, Staphylococcus aureus enterotoxin B. 1993 Eur. J. Immunol. pmid:7680613
Kim YI et al. Augmentation of hepatocyte proliferation by immunosuppressant pretherapy is associated with up-regulation of malondialdehyde production. 1993 Res Exp Med (Berl) pmid:7506444
Hytiroglou P et al. FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. 1993 Transplantation pmid:7506452
Ishizuka J et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. 1993 Transplantation pmid:7506454
Dhar DK et al. Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. 1993 Transplantation pmid:7506456
Nakajima J [The immunosuppressive effects of FK506 on single lung allotransplantation in Japanese monkey (Macaca fuscata)]. 1993 Nihon Kyobu Geka Gakkai Zasshi pmid:7690829
Wenzel-Seifert K and Seifert R Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations. 1993 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7690907
Liu J FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. 1993 Immunol. Today pmid:7691065
Mori T et al. FK-506: a new immunosuppressive agent, failed to reduce cerebral vasospasm after experimental subarachnoid hemorrhage. 1993 J. Vet. Med. Sci. pmid:7691190
Takada K et al. Distribution characteristics of immunosuppressants FK506 and cyclosporin A in the blood compartment. 1993 Biopharm Drug Dispos pmid:7508273
Kawauchi M et al. Prolonged survival of orthotopically transplanted heart xenograft in infant baboons. 1993 J. Thorac. Cardiovasc. Surg. pmid:7693999
Shutter LA et al. Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation. 1993 Neurology pmid:7694189
Dawson TM et al. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7694293
Ahmed SS et al. Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK-506 in rat and human liver microsomes. 1993 J. Pharmacol. Exp. Ther. pmid:7685382
Sewell KL Immunotherapy and other novel therapies, including biologic response modifiers, apheresis, and dietary modifications. 1993 Curr Opin Rheumatol pmid:7685614
Wagner JA et al. Failure of FK 506 to suppress the T cell-mediated immunity of mice to Listeria monocytogenes. 1993 Clin. Exp. Immunol. pmid:7685672
Pilot-Matias TJ et al. High-level synthesis of the 12-kDa human FK506-binding protein in Escherichia coli using translational coupling. 1993 Gene pmid:7685727
Bram RJ et al. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. 1993 Mol. Cell. Biol. pmid:7687744
Heitman J et al. The immunosuppressant FK506 inhibits amino acid import in Saccharomyces cerevisiae. 1993 Mol. Cell. Biol. pmid:7687745
Hirakawa K et al. [The effect of perioperative portal venous inoculation with donor lymphocytes in combination with immunosuppressive agents on rat cardiac allograft survivals]. 1993 Nihon Geka Gakkai Zasshi pmid:7688065
Entani C et al. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/MpJ-lpr/lpr mice. 1993 Nephron pmid:7688103
Namiki Y et al. Tautomeric phenomenon of a novel potent immunosuppressant (FK506) in solution. I. Isolation and structure determination of tautomeric compounds. 1993 J. Antibiot. pmid:7689551
Kondo T et al. [Antitumor sensitivity test, subrenal capsule assay using FK-506: preliminary report]. 1993 Nihon Geka Gakkai Zasshi pmid:7689693
Abu-Elmagd K et al. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). 1993 Ann. Intern. Med. pmid:7689802
Herold KC et al. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. 1993 Transplantation pmid:7678356
Holman MJ et al. FK506-associated thrombotic thrombocytopenic purpura. 1993 Transplantation pmid:7678357
Kawai M et al. Structure-activity profiles of macrolactam immunosuppressant FK-506 analogues. 1993 FEBS Lett. pmid:7678400
Van Duyne GD et al. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. 1993 J. Mol. Biol. pmid:7678431